1) Symptoms from Repeated Intentional and Unintentional Head Impact in Soccer Players2) What's Trending: Nusinersen for treatment of spinal muscular atrophy3) Topic of the Month: Neurology Today® paper on pulmonary embolismThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 28, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Michael Lipton about his paper on repeated head impact in soccer players. Dr. Ted Burns talks with Dr. Richard Finkel about his recent study on nusinersen as a promising treatment for spinal muscular atrophy for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Sofia Barbar on a Neurology Today story about her article on pulmonary embolism. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Lipton has served on the scientific advisory boards of Guerbet and Bracco; has served on the editorial boards of the American Journal of Neuroimaging and Brain Imaging and Behavior; holds a patent on EZ-MAP image processing software; receives publishing royalties from Springer; has been a consultant for Bracco; and has received research support from Philips Medical Systems, NIH/NINDS, NIH/NIA, NIH/NICHD, the Dana Foundation, and the Resurrecting Lives Foundation.Dr. Finkel has served on the scientific advisory boards of Families of SMA, Nationwide Children's Hospital, SMA Europe, Pediatric Neuromuscular Clinical Research Network, and SMA REACH (UK); has received travel funding from Families of SMA, SMA Foundation, and the Muscular Dystrophy Association; has received travel funding and speaker honoraria from Ionis Pharmaceuticals; serves on the editorial boards of Neuromuscular Disorders and the Journal of Neuromuscular Diseases (additionally, spouse serves on editorial board of Arthritis Research and Therapy); his spouse holds patents for Mouse Anti-TCR Zeta Antibody to Southern Biotechnology Associate, Anti-Human TCR Zeta mAb to Upstate Pharmaceuticals, and Anti-Human TCR Zeta mAb to Santa Cruz Biotechnology; he receives publishing royalties from Elsevier; has been a consultant for Ionis Pharmaceuticals, Biogen, Roche, Novartis, Motobridge, Capricor, Lilly, and Summit; spends approximately 30% of his time working with spinal muscular atrophy patients; has received research support from Isis Pharmaceuticals, Biogen, Eli Lilly Pharmaceuticals, Cytokinetics, RevereGen, BMS, Summit, Sarepta, NIH, the Spinal Muscular Atrophy Foundation, Families of Spinal Muscular Atrophy, the Muscular Dystrophy Association, and the Charcot-Marie-Tooth Association; and his spouse receives licensing fee payments for aforementioned patents.All other participants have no disclosures.